|
SECISBP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.85299553479013E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.66879999818903E-08 |
| Normal-vs-Stage2 |
4.76289999995494E-06 |
| Normal-vs-Stage3 |
1.62259095048967E-12 |
| Normal-vs-Stage4 |
5.40967270978854E-12 |
| Stage1-vs-Stage2 |
8.394400E-01 |
| Stage1-vs-Stage3 |
1.124450E-02 |
| Stage1-vs-Stage4 |
2.295800E-03 |
| Stage2-vs-Stage3 |
1.211430E-01 |
| Stage2-vs-Stage4 |
4.737600E-02 |
| Stage3-vs-Stage4 |
4.523400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.9313218519178E-12 |
| Normal-vs-AfricanAmerican |
2.389000E-04 |
| Normal-vs-Asian |
2.31749999968223E-07 |
| Caucasian-vs-AfricanAmerican |
4.136400E-01 |
| Caucasian-vs-Asian |
4.693400E-01 |
| AfricanAmerican-vs-Asian |
7.870800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.28896893158981E-12 |
| Normal-vs-Female |
7.9342998837717E-10 |
| Male-vs-Female |
3.945800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.01559999965417E-07 |
| Normal-vs-Age(41-60Yrs) |
3.93870047687983E-10 |
| Normal-vs-Age(61-80Yrs) |
3.05200309469456E-12 |
| Normal-vs-Age(81-100Yrs) |
3.95020000000246E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.181800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.724400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.190210E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.408400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.320200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.794200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.099600E-02 |
| Classical-VS-Follicular |
2.760000E-01 |
| Classical-VS-Other |
6.534800E-01 |
| Classical-VS-Normal |
1.35610411788889E-11 |
| Tall-VS-Follicular |
2.599000E-03 |
| Tall-VS-Other |
3.909600E-01 |
| Tall-VS-Normal |
1.19379950369591E-10 |
| Follicular-VS-Other |
5.145000E-01 |
| Follicular-VS-Normal |
4.02480000000205E-05 |
| Other-VS-Normal |
3.024000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.12830003515552E-09 |
| Normal-vs-N1 |
4.58029947303373E-10 |
| N0-vs-N1 |
3.709500E-02 |
|
|
